Melanoma

Pan Cancer T secures €4.25 Million in Seed Extension Round to advance next-generation T cell therapies

ROTTERDAM, the Netherlands, July 11, 2024 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T…

5 months ago

GeneType to Enter Canadian and New Zealand Markets

Genomics-based testing brand expands international presence as pilot influencer campaign fuels salesCHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic…

5 months ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024)…

5 months ago

Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

5 months ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and…

5 months ago

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially…

5 months ago

Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE…

5 months ago

Defence’s AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

5 months ago

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000…

5 months ago